Manjula S, Aroor A R, Raja A, Rao S, Rao A
Department of Biochemistry, Kasturba Medical College and Hospital, Manipal, India.
Acta Oncol. 1993;32(1):29-31. doi: 10.3109/02841869309083881.
The urinary 6-hydroxymethylpterin(Pt-6-CH2OH) excretion was determined in 87 patients with brain tumours and in 50 control patients. The Pt-6-CH2OH levels were significantly elevated in all patients with tumours. No difference was observed when malignant tumours were compared with benign neoplasms. Following therapy, the Pt-6-CH2OH levels were partially reduced when compared with control patients and their pre-operative values.
对87例脑肿瘤患者和50例对照患者测定了尿中6-羟甲基蝶呤（Pt-6-CH2OH）的排泄量。所有肿瘤患者的Pt-6-CH2OH水平均显著升高。恶性肿瘤与良性肿瘤相比未观察到差异。治疗后，与对照患者及其术前值相比，Pt-6-CH2OH水平有所下降。
